LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

VitalHub Announces Q3 2025 Conference Call Date

October 20, 2025 | Last Trade: C$9.45 0.00 0.00

TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") announced today that it will release financial results for its third quarter 2025 ended September 30, 2025 after market close on November 6, 2025. The Company will hold a conference call on November 7, 2025 at 9:00am EST, hosted by CEO Dan Matlow and CFO Brian Goffenberg with a Q&A session to follow.

To register for the conference call please visit: https://us06web.zoom.us/webinar/register/WN_CDYke6WeQXGh1QeEQ4xrqg

About VitalHub

VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit www.vitalhub.com and LinkedIn.

Contact Information

Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page